Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
May 19 2022 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of ocular diseases, today announced
that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug
Vision, will present an update on the clinical development plan for
GB-102 in wet age-related macular degeneration, and will be part of
a subsequent panel discussion at the upcoming Clinical Trials at
the Summit Meeting, to be held in person at the Hyatt Regency Lake
Tahoe in Nevada, as well as virtually, on May 21, 2022.
Clinical Trials at the Summit brings together a diverse group of
experts from around the world to discuss ongoing clinical trials
and the latest data, with the goal of accelerating advances in
vitreoretinal care. Details for the event are listed below and
available on the Clinical Trials at the Summit website.
Presentation: Update on GB-102 in nAMD
Presenter: Parisa Zamiri, MD, PhD Session: Clinical trials
addressing nAMD, Session #2 Date and Time: Saturday May 21, 2022;
2:20 PM – 2:50 PM PDT
A copy of the presentation will be made available in the
Investors and Media section of the company’s website – in the
Medical Events and Publications tab – at the time of the
presentation.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for ocular diseases. The
company’s diversified portfolio is designed to treat
vision-threatening diseases of the retina, optic nerve, and cornea,
by either maintaining effective drug levels in ocular tissues for
long periods of time, using innovative technologies, such as
injectable sustained-release formulations, or by curing diseases
with gene therapies. Graybug’s most advanced drug candidate,
GB-102 is a microparticle formulation of a
pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related
macular degeneration designed for a twice-per-year intravitreal
injection. GB-102 has the potential to also benefit patients with
diabetic retinopathy. GB-401 is a first-in-class
implant formulation containing a novel prodrug of timolol for the
treatment of primary open-angle glaucoma (POAG) designed for a
twice-per-year intravitreal injection with a proprietary
applicator. GB-501 is an adeno-associated virus
(AAV) gene therapy with Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) to treat corneal clouding
caused by mucopolysaccharidosis type 1 (MPS1), a lysosomal storage
disorder. GB-601 is being developed as a
long-acting formulation of a novel cGMP analog to address
hereditary retinal diseases like retinitis pigmentosa, a group of
genetic disorders that involve a loss of cells in the retina.
GB-701 is being developed as a long-acting
formulation of a potent factor B inhibitor targeting the complement
cascade which plays a role in AMD. Founded in 2011 based on
technology licensed from the Johns Hopkins University School of
Medicine, Graybug has offices in Redwood City, California and in
Baltimore, Maryland. For more information, please visit
www.graybug.vision.
Investor ContactIR@graybug.vision(650)
487-2409 |
Media Contactmedia@graybug.vision(404)
384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024